Phase III Study Results Revealed at ASCO Demonstrate Imfinzi Enhances Survival in Limited-Stage Small Cell Lung Cancer.
Phase III Trial Data Presented at ASCO Show Imfinzi Improves Survival in Limited-Stage Small Cell Lung Cancer During the American Society of Clinical Oncology (ASCO) annual meeting, new Phase III trial data was unveiled, demonstrating that Imfinzi (durvalumab), a product of AstraZeneca, significantly improves survival rates in patients with limited-stage small cell lung cancer (SCLC) […]